Current Status
Not Enrolled
Price
Free
Get Started

Global ASCVD Trends and Emerging Strategies

Program Director

Peter Libby, MD

Program Director

Raul D Santos, MD, MSc, PhD

The IAS has developed the worldwide effort aimed at health care professionals to comprehensively address the matter of LDL-C attributable risk in the prevention of Major Adverse Cardiology Events (MACE) and mortality  This will be accomplished through a series of nine (9) videos presented by some of the most recognizable and prominent leaders in cardiology and lipid medicine from across the globe. 

Importantly, the videos will emphasize the translation of current guidelines and evidence into practice approaches that heighten both clinical and patient success.  Every video, based on real-world issues and evidence, will focus on implementing practical physician and patient strategies. 

The videos are presented in
English, but we have added subtitles in four (4) additional languages:  Arabic, Spanish, Portuguese and Chinese.  

            Click on the button of your preferred language below.

Pre-Activty Information

NAFLD/NASH and ASCVD Connection: Final Messages

Patient Identification and Risk Stratification

ASCVD and NAFLD/NASH: the Background of the Connection

Part 4: Round table with the experts: Where do we stand in our battle against the ravages of diabetes?

Parte 4, Mesa redonda com os especialistas – Onde estamos em nossa batalha contra os danos do diabetes?

Parte 3, Sessão B – Opções terapêuticas para prevenção de doenças cardiovasculares

Parte 3, Sessão A – Uma hierarquia de abordagens de tratamento com base na gravidade para o paciente DM2 com DCVA

Parte 2 – Combatendo a aterosclerose: avaliando o risco CV para o paciente com DM2

Parte 1 – A história na batalha da insulina e glucagon

Part 3 – Session B: Therapeutic options for prevention of cardiovascular disease

Part 3 – Session A: A Hierarchy of Treatment Approaches based on Severity for the T2DM Patient with ASCVD

Part 2: Combating Atherosclerosis: Assessing CV Patient Risk for the T2DM Patient

Part 1: The History in the Battle of Insulin and Glucagon

Modera resumen de los mensajes claves de las conferencias – Maria Cristina Izar (Brasil)

Discusión Foro 4 – Panelist Roopa Mehta (Mexico)

Nuevas terapias para la HF grave – Paola Varleta (Chile)

Eficacia y seguridad de Lomitapida en HF homocigota – Dirk Blom (SudAfrica)

Inhibidores PCSK9 en la HF grave – Maria Cristina Izar (Brasil)

« » page 1 / 13